Campaign
ProVascTec stage
Cell Therapy / BioTech
A UCC spin-out which developed a novel mechanism for the efficient delivery of cell therapies for the treatment of patients suffering from blocked lower-leg arteries.
€
900,000Funding goal
€
933,930Invested
68Investors
Company Summary :
test